Background: To determine if alcohol consumption is a risk factor for obstructive sleep apnea (OSA) and nocturnal oxygen desaturation. Methods: This case–control study evaluated patients with confirmed OSA and a control group using polysomnography (PSG). Two doctors who have worked in this field for more than 5 years provided a blinded interpretation of the patients’ monitoring results. Logistic regression models were used to identify the odds ratio (OR) for alcohol consumption on OSA. Results: A total of 793 patients were enrolled in this study. Compared with those who did not consume alcohol, those consuming alcohol had a higher risk of OSA (OR 2.03, 95% CI 1.30–3.17) after adjustment. Regarding the risk of OSA after adjusting for former drinkers and current ones, the ORs were 1.96 (95% CI 1.19–3.22) and 2.22 (95% CI 1.06–4.63), respectively. And the P for trend = 0.002. The β of former drinkers and the current ones were 3.448 and 4.560 after adjustment; P for trend was 0.006. The relationship may have gender difference, and alcohol consumption was associated with AHI in female significantly (β = 10.190 and 15.395 for former and current drinkers, respectively, in females after adjustment, P for trend = 0.002). Conclusions: In this study, we found that alcohol consumption was an independent risk factor of OSA and OSA with hypoxia, and alcohol consumption was related to AHI significantly after adjustment, especially in female. In order to reduce the risk and severity of OSA, it is suggested that people should avoid drinking, and drinkers should abstain from drinking.

A 68-year-old man presented with acute coronary syndrome (ACS). The glycoprotein/IIb/IIIa receptor antagonist tirofiban was administered to the patient to treat a right coronary artery slow flow detected during percutaneous coronary intervention. The patient developed very severe thrombocytopenia 8 h after tirofiban infusion with no signs of bleeding. Antiplatelet medication was discontinued immediately, methylprednisolone was administered and platelets were transfused. Thrombopoietin (TPO) was also applied to the patient as recommended by a hematology consultant. As a result, the patient had in‑stent thrombosis and cerebral infarction, then another sirolimus‑eluting stent was implanted in the proximal right coronary artery and intensive anti‑platelet as well as intermittent dehydration to reduce intracranial pressure, and protection of the nervous system function treatment was also provided. The patient was left with a decreased muscle strength in the right limb muscle and fine movement disorder, which may have lead to a poor prognosis. To the best of our knowledge, this is the first case report of tirofiban‑induced severe thrombocytopenia with secondary in‑stent thrombosis and cerebral infarction from China. The experience of the diagnosis and treatment of this case may shed some light on the clinical use of TPO in tirofiban-induced thrombocytopenia.

To determine if obstructive sleep apnea (OSA) is a risk factor for early stent thrombosis (EST; within 30 days) after percutaneous coronary intervention (PCI). This case–control study involved 23 patients with angiographically confirmed EST after PCI (case group) and 92 PCI patients (control group) who did not develop stent thrombosis during a 2-year follow-up. Patients with symptoms and characteristics consistent with OSA (hereinafter referred to as OSA) were identified using the Berlin questionnaire, and the general characteristics of the patients and their treatments as well as outcomes were recorded. The odds ratios (ORs) for OSA were calculated. Additionally, the association between OSA and EST in patients with different conventional cardiovascular risk factors was analyzed. The crude OR for OSA was 4.17 (95% confidence interval [CI]: 1.60–10.84, P = 0.003). After adjusting for other risk factors of EST, the OR for OSA remained significant. In participants with no or one conventional cardiovascular disease risk factor, we found a significant association between OSA and EST (OR: 17.00, 95% CI: 2.33–124.19, P = 0.005). OSA is an independent risk factor for EST. This conclusion was further supported by the finding that in patients with few conventional cardiovascular risk factors, the contribution of OSA to EST was more obvious.

Background: Prophylactic medications are believed to reduce risks of gastrointestinal (GI) bleeding after percutaneous coronary intervention (PCI). However, their true effectiveness in preventing GI bleeding is still unknown. Methods: The clinical data of 36,870 patients treated with PCI from January 2010 to July 2017 were retrospectively analyzed. The trend in the prophylactic use of mucosal protective agents and proton pump inhibitors was analyzed. Results: A total of 36,870 patients were included with a mean age of 60 ± 18 years. In patients treated with primary PCI for ST-segment elevation myocardial infarction, prophylactic medications were associated with a significantly lower incidence of postprocedure GI bleeding in comparison with no medication (1.072%, 52/4852 vs. 2.747%, 25/910; P < 0.001). In patients with CRUSADE scores >40, prophylactic medications were associated with a significantly lower incidence of postprocedure GI bleeding in comparison with not using prophylactic medications (0.679%, 21/3093 vs. 1.899%, 20/1053; P = 0.001). Conclusions: Prophylactic medications were associated with significantly lower incidence of postprocedure 30-day GI bleeding in patients with primary PCI for ST-segment elevation myocardial infarction or CRUSADE scores >40.